Logo

On this page you will find useful information regarding which patients should be initiated on UPTRAVI®, guidance on prescribing and administering UPTRAVI®, access to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension proceedings, and recommendations for screening and diagnosing patients with scleroderma or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).

Prescribing UPTRAVI®

UPTRAVI® SmPC and patient information leaflet

Access the UPTRAVI® SmPC and patient information leaflet.

UPTRAVI® titration guide

Guidance on correctly starting your patient on their UPTRAVI® journey.

UPTRAVI® patient guide

The My UPTRAVI® Treatment Guide explains the dosing process and supports patients along their UPTRAVI® journey.

PAH guidelines and organisations

2015 ESC/ERS guidelines


2018 WSPH proceedings


Identifying PAH in patients with scleroderma

Scleroderma information guide

Learn how PAH can impact patients with scleroderma.

Scleroderma referral guide

Learn about the investigation and referral pathways for patients with scleroderma and suspected PAH.

Identifying PAH in patients with CHD

CHD information guide

Learn how PAH can impact patients with CHD.

CHD referral guide

Learn about the investigation and referral pathways of patients with CHD and suspected PAH.

Continue reading

Efficacy

Discover how UPTRAVI® can provide long-term benefits for patients with PAH.[1]

Safety and tolerability

UPTRAVI® has a well-characterised and generally manageable safety profile.[1][2]

Initiation and dosing

Adding UPTRAVI® is recommended at the first sign of intermediate risk.[3][4]

Request medical information


Contact a Janssen representative


Stay in touch


CHD, congenital heart disease; ERS, European Respiratory Society; ESC, European Society of Cardiology; PAH, pulmonary arterial hypertension; PHA, Pulmonary Hypertension Association; WSPH, World Symposium on Pulmonary Hypertension

UPTRAVI® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING

CP-220222 | May 2021

References

[1]
Sitbon O et al. N Engl J Med 2015; 373:2522–2533.
[2]
UPTRAVI® SmPC, February 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/uptravi-epar-product-information_en.pdf (last accessed May 2021).
[3]
Galiè N et al. Eur Heart J 2016; 37(1):67–119.
[4]
Galiè N et al. Eur Respir J 2019; 53(1):1801889.
© Janssen Pharmaceutica NV 2021. This site is published by Janssen Pharmaceutica NV which is solely responsible for its content. It is intended for European, Middle Eastern and African Healthcare professionals.
Logo